Nendratareotide uzatansine

N/A

Report date: 2026/03/04 18:07:00

Base Information

Drug NameNendratareotide uzatansine
Drug Alias NameBTP-277PEN-221
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionSomatostatin receptor 2 modulatorsDNA synthesis inhibitorsApoptosis inhibitors +[5] 
TargetsSomatostatin receptor 2Tubulin
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, NeuroendocrineNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTarveda Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTarveda Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, NeuroendocrineNeuroendocrine Tumors

Other Information

ATC CodeN/A
Related LinksN/A